Dataset related to article "Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer Long-term results and factors predictive for outcome and toxicity"
| Main Authors: | franzese, ciro, badalamenti, marco, di brina, lucia, d'agostino, giuseppe, franceschini, davide, comito, tiziana, clerici, elena, navarria, pierina, reggiori, giacomo, mancosu, pietro, tomatis, stefano, scorsetti, marta |
|---|---|
| Format: | info dataset Journal |
| Terbitan: |
, 2020
|
| Subjects: | |
| Online Access: |
https://zenodo.org/record/4384553 |
| ctrlnum |
4384553 |
|---|---|
| fullrecord |
<?xml version="1.0"?>
<dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><creator>franzese, ciro</creator><creator>badalamenti, marco</creator><creator>di brina, lucia</creator><creator>d'agostino, giuseppe</creator><creator>franceschini, davide</creator><creator>comito, tiziana</creator><creator>clerici, elena</creator><creator>navarria, pierina</creator><creator>reggiori, giacomo</creator><creator>mancosu, pietro</creator><creator>tomatis, stefano</creator><creator>scorsetti, marta</creator><date>2020-12-22</date><description>This record contains raw data related to article “Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity"
Introduction: Stereotactic body radiation therapy (SBRT) is considered an effective and safe treatment in patients with low- and intermediate-risk prostate cancer (PC). However, due to a lack of long-term follow-up and late toxicity data, this treatment is not universally accepted. The present study aimed to evaluate outcome and early and late toxicity in a cohort of patients with low- and intermediate-risk PC treated prospectively with linear accelerator (linac)-based SBRT.
Patients and methods: Patients with low- or intermediate-risk (NCCN criteria) PC were included. All patients received linac-based SBRT to 35 Gy in 5 fractions delivered on alternate days. Endpoints were toxicity, biochemical relapse-free survival (BRFS), metastatic progression-free survival (mPFS), and overall survival (OS).
Results: From 2012 to 2018, 178 patients were treated. Median baseline prostate-specific antigen (iPSA) was 6.37 ng/ml (range 1.78-20). Previous transurethral resection of the prostate (TURP) was present in 23 (12.9%) patients. Median follow-up was 58.9 months (range 9.7-89.9). BRFS rates at 1, 3, and 5 years were 98.3 (95% confidence interval, CI, 94.7-99.4%), 94.4 (95%CI 89.4-97), and 91.6% (95%CI 85.4-95.2), respectively. In univariate analysis, performance status (PS), iPSA, and nadir PSA (nPSA) were correlated with BRFS. In multivariable analysis iPSA and nPSA remained significant. BRFS rates at 5 years were 94.9% (95%CI 86.8-98) for International Society of Urological Pathology (ISUP) grade group 1, 93.2% (95%CI 80.5-97.7) for ISUP group 2, and 74.8% (95%CI 47.1-89.5) for ISUP group 3. At 1, 3, and 5 years, mPFS rates were 98.8 (95%CI 95.5-99.7), 96.2 (95%CI 91.9-98.3), and 92.9% (95%CI 87.2-96.2), respectively; OS rates were 100, 97.2 (95%CI 92.9-98.9), and 95.1% (95%CI 90-97.6), respectively. One (0.56%) case of grade 3 acute genitourinary (GU), one case of acute gastrointestinal (GI), and one case of grade 3 late GU toxicity were observed. GI toxicity positively correlated with prostate volume.
Conclusion: At long-term follow-up, linac-based SBRT continues to be a valid option for the management localized PC. Biochemical control remains high at 5 years, albeit with some concerns regarding the optimal schedule for unfavorable intermediate-risk PC. Considering the excellent prognosis, patient selection is crucial for prevention of severe late toxicity.</description><identifier>https://zenodo.org/record/4384553</identifier><identifier>10.5281/zenodo.4384553</identifier><identifier>oai:zenodo.org:4384553</identifier><relation>doi:10.1007/s00066-020-01619-7</relation><relation>pmid:32303782</relation><relation>doi:10.5281/zenodo.4384552</relation><relation>url:https://zenodo.org/communities/humanitasirccs</relation><rights>info:eu-repo/semantics/restrictedAccess</rights><subject>Gantry</subject><subject>LINAC</subject><subject>Prostate-specific antigen</subject><subject>Radiotherapy</subject><subject>SBRT</subject><title>Dataset related to article "Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity"</title><type>Other:info:eu-repo/semantics/other</type><type>Other:dataset</type><recordID>4384553</recordID></dc>
|
| format |
Other:info:eu-repo/semantics/other Other Other:dataset Journal:Journal Journal |
| author |
franzese, ciro badalamenti, marco di brina, lucia d'agostino, giuseppe franceschini, davide comito, tiziana clerici, elena navarria, pierina reggiori, giacomo mancosu, pietro tomatis, stefano scorsetti, marta |
| title |
Dataset related to article "Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity" |
| title_sub |
Long-term results and factors predictive for outcome and toxicity" |
| publishDate |
2020 |
| topic |
Gantry LINAC Prostate-specific antigen Radiotherapy SBRT |
| url |
https://zenodo.org/record/4384553 |
| contents |
This record contains raw data related to article “Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity"
Introduction: Stereotactic body radiation therapy (SBRT) is considered an effective and safe treatment in patients with low- and intermediate-risk prostate cancer (PC). However, due to a lack of long-term follow-up and late toxicity data, this treatment is not universally accepted. The present study aimed to evaluate outcome and early and late toxicity in a cohort of patients with low- and intermediate-risk PC treated prospectively with linear accelerator (linac)-based SBRT.
Patients and methods: Patients with low- or intermediate-risk (NCCN criteria) PC were included. All patients received linac-based SBRT to 35 Gy in 5 fractions delivered on alternate days. Endpoints were toxicity, biochemical relapse-free survival (BRFS), metastatic progression-free survival (mPFS), and overall survival (OS).
Results: From 2012 to 2018, 178 patients were treated. Median baseline prostate-specific antigen (iPSA) was 6.37 ng/ml (range 1.78-20). Previous transurethral resection of the prostate (TURP) was present in 23 (12.9%) patients. Median follow-up was 58.9 months (range 9.7-89.9). BRFS rates at 1, 3, and 5 years were 98.3 (95% confidence interval, CI, 94.7-99.4%), 94.4 (95%CI 89.4-97), and 91.6% (95%CI 85.4-95.2), respectively. In univariate analysis, performance status (PS), iPSA, and nadir PSA (nPSA) were correlated with BRFS. In multivariable analysis iPSA and nPSA remained significant. BRFS rates at 5 years were 94.9% (95%CI 86.8-98) for International Society of Urological Pathology (ISUP) grade group 1, 93.2% (95%CI 80.5-97.7) for ISUP group 2, and 74.8% (95%CI 47.1-89.5) for ISUP group 3. At 1, 3, and 5 years, mPFS rates were 98.8 (95%CI 95.5-99.7), 96.2 (95%CI 91.9-98.3), and 92.9% (95%CI 87.2-96.2), respectively; OS rates were 100, 97.2 (95%CI 92.9-98.9), and 95.1% (95%CI 90-97.6), respectively. One (0.56%) case of grade 3 acute genitourinary (GU), one case of acute gastrointestinal (GI), and one case of grade 3 late GU toxicity were observed. GI toxicity positively correlated with prostate volume.
Conclusion: At long-term follow-up, linac-based SBRT continues to be a valid option for the management localized PC. Biochemical control remains high at 5 years, albeit with some concerns regarding the optimal schedule for unfavorable intermediate-risk PC. Considering the excellent prognosis, patient selection is crucial for prevention of severe late toxicity. |
| id |
IOS16997.4384553 |
| institution |
ZAIN Publications |
| institution_id |
7213 |
| institution_type |
library:special library |
| library |
Cognizance Journal of Multidisciplinary Studies |
| library_id |
5267 |
| collection |
Cognizance Journal of Multidisciplinary Studies |
| repository_id |
16997 |
| subject_area |
Multidisciplinary |
| city |
Stockholm |
| province |
INTERNASIONAL |
| shared_to_ipusnas_str |
1 |
| repoId |
IOS16997 |
| first_indexed |
2022-06-06T04:55:40Z |
| last_indexed |
2022-06-06T04:55:40Z |
| recordtype |
dc |
| _version_ |
1734903688413052928 |
| score |
17.608942 |